Efficacy of individualized treatment with sunitinib versus standardised treatment with sunitinib or pazopanib in patients with metastatic renal cell carcinoma

Trial Profile

Efficacy of individualized treatment with sunitinib versus standardised treatment with sunitinib or pazopanib in patients with metastatic renal cell carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Sunitinib (Primary) ; Pazopanib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 20 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top